Schedule 13G ownership disclosure

XILIO THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 98422T100

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Bain Capital Life Sciences Fund II, L.P.

    Shares: 992,111 · Class: 1.3%

  • BCIP Life Sciences Associates, LP

    Shares: 120,833 · Class: 0.2%

  • BCLS II Equity Opportunities, LP

    Shares: 6,259,742 · Class: 8.5%

  • BCLS II Investco, LP

    Shares: 0 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-054804
Form type
SCHEDULE 13G/A
Filer
Bain Capital Life Sciences Fund II, L.P.
CIK
CIK 1773187
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub